https://www.selleckchem.com/pr....oducts/pf-06700841.h
acaftor/ivacaftor regimen results in sustained CFTR modulation in pwCF ≥ 12years of age. PBPK modeling indicates that immediate transition to the elexacaftor/tezacaftor/ivacaftor regimen from an ivacaftor, lumacaftor/ivacaftor, or tezacaftor/ivacaftor regimen results in sustained CFTR modulation in pwCF ≥ 12 years of age. Managed entry agreements (MEAs) consist of a set of instruments to reduce the uncertainty and the budget impact of new high-priced medicines; however, there are concerns. There is a need to critically appraise MEAs
Like
Comment
Share
